Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors
NCT ID: NCT06150183
Last Updated: 2026-01-23
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
ACTIVE_NOT_RECRUITING
Clinical Phase
PHASE1
Total Enrollment
41 participants
Study Classification
INTERVENTIONAL
Study Start Date
2023-11-30
Study Completion Date
2028-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this first-in-human study is to find out if BNT314 is safe when it is used alone in patients with different types of cancer.
This is a dose escalation study in which patients will be assigned to multiple dose levels (DLs) of BNT314 given alone. By escalating the dose with a small group of patients, the Maximum Tolerated Dose which is the highest dose with acceptable safety and manageable side effects, or the maximum administered dose will be investigated.
This is a dose escalation study in which patients will be assigned to multiple dose levels (DLs) of BNT314 given alone. By escalating the dose with a small group of patients, the Maximum Tolerated Dose which is the highest dose with acceptable safety and manageable side effects, or the maximum administered dose will be investigated.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
NCT06750185
Advanced Solid Tumor
RECRUITING
PHASE1
BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors
NCT04455620
Solid Tumor
TERMINATED
PHASE1/PHASE2
A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors
NCT07147348
Advanced Solid Tumor
RECRUITING
PHASE1/PHASE2
A Study to Evaluate Safety and Tolerability of BPT567 in Patients With Advanced Solid Tumors
NCT06779851
Advanced Solid Tumors
RECRUITING
PHASE1
Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors
NCT05262530
Solid Tumor
TERMINATED
PHASE1/PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a multicenter, multinational safety study in patients with metastatic or advanced malignant solid tumors for whom, at the discretion of the investigator, there is no available standard therapy likely to confer clinical benefit, evaluating the safety, tolerability, preliminary antitumor activity, pharmacokinetics (PK), pharmacodynamics, and immunogenicity of BNT314.
During dose escalation, BNT314 will be administered to patients via one infusion in periodic cycles.
Additional cohorts (backfill cohorts) administering BNT314 as monotherapy will assign patients to specific DLs, based on the emerging safety, PK, and pharmacodynamic data. This would allow for further assessment of dose- and exposure-response relationships for clinical activity, safety, and tolerability to support BNT314 dose optimization.
The treatment period will last until progressive disease (PD), confirmed PD (as per immune Response Evaluation Criteria in Solid Tumors \[iRECIST\]), unacceptable toxicity, or withdrawal of consent, whichever happens first.
The maximum duration of BNT314 administration in this study is 2 years.
During dose escalation, BNT314 will be administered to patients via one infusion in periodic cycles.
Additional cohorts (backfill cohorts) administering BNT314 as monotherapy will assign patients to specific DLs, based on the emerging safety, PK, and pharmacodynamic data. This would allow for further assessment of dose- and exposure-response relationships for clinical activity, safety, and tolerability to support BNT314 dose optimization.
The treatment period will last until progressive disease (PD), confirmed PD (as per immune Response Evaluation Criteria in Solid Tumors \[iRECIST\]), unacceptable toxicity, or withdrawal of consent, whichever happens first.
The maximum duration of BNT314 administration in this study is 2 years.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Advanced Malignant Solid Tumor
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SEQUENTIAL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BNT314 Monotherapy
Escalating dose levels and backfill cohorts
Group Type
EXPERIMENTAL
BNT314
Intervention Type
BIOLOGICAL
Intravenous infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BNT314
Intravenous infusion
Intervention Type
BIOLOGICAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Have the ability to voluntarily give informed consent by signing and dating the informed consent form (ICF) before initiation of any study-specific procedures.
2. Are willing and able to comply with scheduled visits, treatment schedule, laboratory tests, lifestyle restrictions, and other requirements of the study. This includes that they are able to understand and follow study-related instructions.
3. Are ≥18 years of age at the time of giving informed consent.
4. Have measurable disease according to RECIST v1.1.
5. Have a life expectancy of \>3 months.
6. Have Eastern Cooperative Oncology Group Performance Status score of 0 or 1 at screening.
7. Have adequate coagulation function at screening as determined by:
* International normalized ratio or prothrombin time ≤1.5 × upper limit normal (ULN; unless on therapeutic anticoagulants with values within therapeutic window).
* Activated partial thromboplastin time ≤1.5 × ULN (unless on therapeutic anticoagulants with values within therapeutic window).
8. Have adequate bone marrow/hematologic function at screening as determined by:
* Absolute neutrophil count (ANC) ≥1.5 × 10\^9/L (≥1500/μL) (patients may not use granulocyte colony stimulating factor or granulocyte-macrophage colony stimulating factor to achieve these ANC levels in the past 7 days).
* Platelet count ≥100 × 10\^9/L (≥100,000/μL).
* Hemoglobin ≥9 g/dL.
* Any blood transfusions ≤28 days before first dose of study treatment should be documented.
9. Have adequate hepatic function at screening as determined by:
* Total bilirubin (Tbili) ≤1.5 × ULN OR direct bilirubin ≤ULN for patients with Tbili levels \>1.5 × ULN. Patients with Gilbert's syndrome must have a Tbili \<3 mg/dL and direct bilirubin ≤ULN.
* Alanine aminotransferase and aspartate aminotransferase ≤2.5 ULN for patients with or without liver metastases.
* Albumin ≥30 g/L.
10. Have adequate renal function at screening as determined by glomerular filtration rate ≥45 mL/min/1.73 m\^2 according to the abbreviated Modification of Diet in Renal Disease equation.
11. Have adequate pancreas function at screening as determined by amylase and lipase with no signs and symptoms of pancreatitis.
12. Patients of childbearing potential (POCBP) must have a negative urine or blood beta human chorionic gonadotropin test at screening. Patients that are postmenopausal or permanently sterilized (verified by medical records) will not be considered POCBP, and therefore are not required to undergo pregnancy testing.
13. POCBP must agree to practice a highly effective form of contraception and to require their male partners to use condoms coated with a spermicidal agent, starting at Visit D1 and thereafter until 120 days after receiving the last study treatment.
14. POCBP must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during study, starting at Visit D1 and thereafter until 120 days after receiving the last study treatment.
15. Males who are sexually active and have not had a bilateral vasectomy or orchidectomy must agree to use condoms coated with a spermicidal agent and to require their female partners to practice a highly effective form of contraception during the study, starting at Visit D1 and thereafter until 120 days after receiving the last study treatment.
16. Males must be willing to refrain from sperm donation, starting at Visit D1 and thereafter until 120 days (one sperm cycle) after receiving the last study treatment.
17. Patients must have a histologically confirmed advanced malignant solid tumor, having experienced disease progression on or after standard therapy, or were intolerant of or not eligible for standard therapy.
2. Are willing and able to comply with scheduled visits, treatment schedule, laboratory tests, lifestyle restrictions, and other requirements of the study. This includes that they are able to understand and follow study-related instructions.
3. Are ≥18 years of age at the time of giving informed consent.
4. Have measurable disease according to RECIST v1.1.
5. Have a life expectancy of \>3 months.
6. Have Eastern Cooperative Oncology Group Performance Status score of 0 or 1 at screening.
7. Have adequate coagulation function at screening as determined by:
* International normalized ratio or prothrombin time ≤1.5 × upper limit normal (ULN; unless on therapeutic anticoagulants with values within therapeutic window).
* Activated partial thromboplastin time ≤1.5 × ULN (unless on therapeutic anticoagulants with values within therapeutic window).
8. Have adequate bone marrow/hematologic function at screening as determined by:
* Absolute neutrophil count (ANC) ≥1.5 × 10\^9/L (≥1500/μL) (patients may not use granulocyte colony stimulating factor or granulocyte-macrophage colony stimulating factor to achieve these ANC levels in the past 7 days).
* Platelet count ≥100 × 10\^9/L (≥100,000/μL).
* Hemoglobin ≥9 g/dL.
* Any blood transfusions ≤28 days before first dose of study treatment should be documented.
9. Have adequate hepatic function at screening as determined by:
* Total bilirubin (Tbili) ≤1.5 × ULN OR direct bilirubin ≤ULN for patients with Tbili levels \>1.5 × ULN. Patients with Gilbert's syndrome must have a Tbili \<3 mg/dL and direct bilirubin ≤ULN.
* Alanine aminotransferase and aspartate aminotransferase ≤2.5 ULN for patients with or without liver metastases.
* Albumin ≥30 g/L.
10. Have adequate renal function at screening as determined by glomerular filtration rate ≥45 mL/min/1.73 m\^2 according to the abbreviated Modification of Diet in Renal Disease equation.
11. Have adequate pancreas function at screening as determined by amylase and lipase with no signs and symptoms of pancreatitis.
12. Patients of childbearing potential (POCBP) must have a negative urine or blood beta human chorionic gonadotropin test at screening. Patients that are postmenopausal or permanently sterilized (verified by medical records) will not be considered POCBP, and therefore are not required to undergo pregnancy testing.
13. POCBP must agree to practice a highly effective form of contraception and to require their male partners to use condoms coated with a spermicidal agent, starting at Visit D1 and thereafter until 120 days after receiving the last study treatment.
14. POCBP must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during study, starting at Visit D1 and thereafter until 120 days after receiving the last study treatment.
15. Males who are sexually active and have not had a bilateral vasectomy or orchidectomy must agree to use condoms coated with a spermicidal agent and to require their female partners to practice a highly effective form of contraception during the study, starting at Visit D1 and thereafter until 120 days after receiving the last study treatment.
16. Males must be willing to refrain from sperm donation, starting at Visit D1 and thereafter until 120 days (one sperm cycle) after receiving the last study treatment.
17. Patients must have a histologically confirmed advanced malignant solid tumor, having experienced disease progression on or after standard therapy, or were intolerant of or not eligible for standard therapy.
Exclusion Criteria
1. Patients that have uncontrolled intercurrent illness, including but not limited to:
* Ongoing or active infection requiring treatment with anti-infective therapy administered less than 2 weeks prior to first dose.
* Symptomatic congestive heart failure (Grade III or IV as classified by the New York Heart Association), unstable angina pectoris, or symptomatic untreated cardiac arrhythmia. Treated and/or asymptomatic cardiac arrythmia/atrial fibrillation will be allowed.
* History of arterial thrombosis or pulmonary embolism within 6 months before the first dose of study treatment.
* History of myocardial infarction within 6 months before the first dose of study treatment.
* Uncontrolled hypertension defined as systolic blood pressure ≥160 mm Hg and/or diastolic blood pressure ≥100 mm Hg, despite optimal medical management.
* Prolonged QTc interval at baseline of ≥470 milliseconds using Fridericia's QT correction formula.
* Ongoing or recent (within one year of screening) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk for immune-related adverse events.
* History of:
* Grade 2 immune-mediated myocarditis/colitis/pneumonitis that led to checkpoint inhibitor (CPI) discontinuation. Patients experiencing other Grade 2 immune-mediated adverse events that led to CPI discontinuation, require discussion with the sponsor.
* Any Grade ≥3 immune-mediated adverse events that led to CPI discontinuation.
* Patients with Grade 3 adverse events that led to CPI discontinuation but resolved within 21 days without sequalae may also be considered for discussion with the sponsor.
* History of chronic liver disease (e.g., alcoholic hepatitis or nonalcoholic steatohepatitis, drug-related or autoimmune hepatitis) or evidence of hepatic cirrhosis.
* History of non-treated intracerebral arteriovenous malformation (shunts), non-treated cerebral aneurysm, spinal cord compression (from disease), carcinomatous meningitis, or stroke will be excluded.
* History of acute or chronic pancreatitis of any etiology within 6 weeks prior to the start of study treatment.
* Ongoing pneumonitis or history of noninfectious pneumonitis that has required steroids or evidence of interstitial lung disease.
* Transient ischemic attack less than one month prior to screening will be excluded.
* History of brain/central nervous system (CNS) metastases. Patients with newly identified or known unstable or symptomatic CNS metastases will be excluded. Patients with previously treated brain metastases are allowed provided lesions are radiologically stable (i.e., without evidence of progression) for at least 28 days by repeat imaging, latest imaging performed maximum 6 weeks prior to Cycle 1, Day 1.
* Serious, non-healing wound, skin ulcer (of any grade), or bone fracture will be excluded.
* Other concurrent severe and/or uncontrolled medical condition that would, in the investigator's judgment, contraindicate patient participation in this clinical study (e.g., acute or chronic pancreatitis, active hepatitis). Known primary immunodeficiencies, either cellular (e.g., DiGeorge syndrome, T-cell negative severe combined immunodeficiency \[SCID\] or combined T- and B-cell immunodeficiencies (e.g., T- and B-cell negative SCID, Wiskott Aldrich syndrome, ataxia telangiectasia, common variable immunodeficiency).
* Major surgery within 3 weeks before signature of the ICF unless fully recovered from the surgery in the opinion of the investigator.
* Any positive test for hepatitis B (defined as positive for hepatitis B surface antigen or hepatitis B virus DNA), indicating acute or chronic infection.
* Any positive test for hepatitis C (defined as positive for hepatitis C virus antibody or hepatitis C virus RNA), indicating acute or chronic infection.
2. Prior therapy:
* Radiotherapy within 14 days prior to first BNT314 administration. Palliative radiotherapy will be allowed, but not to target lesions.
* Any epithelial cell adhesion molecule- or 4-1BB-targeting treatment.
* Treatment with an anticancer agent within 4 weeks or for systemic therapies after at least five half-lives of the drug, whichever is shorter, prior to study treatment administration.
* Patient has received any investigational agent (including investigational vaccines) or used an invasive investigational medical device within 28 days before the planned first dose of BNT314 or is currently enrolled in an (another) interventional study. Patients who are in the follow-up phase of an interventional study may participate if they have not received an investigational agent within 28 days (or five half-lives, whichever is longer) of the first dose of BNT314.
* Patient has a condition requiring systemic treatment with either corticosteroids (\>10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days of the first dose of BNT314. Inhaled or topical steroids, and adrenal or pituitary replacement steroid \>10 mg daily prednisone or equivalent, are permitted in the absence of active autoimmune disease.
* Patient has received granulocyte or granulocyte/macrophage colony stimulating factor (G-CSF/GM-CSF) support within 4 weeks prior to first BNT314 administration or is chronically transfusion dependent; G-CSF and other hematopoietic factors may be used in the management of acute toxicity (such as febrile neutropenia) or prophylactically, when clinically indicated at the investigator's discretion.
* Received any live vaccine within 30 days prior to the start of study treatment.
3. Known alcohol dependency within 6 months enrollment in this study.
4. Planned enrollment in another study of an IMP, starting after Visit D1 and continuously until the last planned visit in this study.
5. Have a medical, psychological, or social condition which, in the opinion of the investigator, could compromise their wellbeing if they participate in the study, or that could prevent, limit, or confound the protocol specified assessments or procedures, or that could impact adherence to protocol-described requirements.
6. Are subject to exclusion periods from another investigational study.
7. Are vulnerable individuals as per International Council for Harmonisation E6 definition, i.e., are individuals whose willingness to participate in a clinical study may be unduly influenced by the expectation, whether justified or not, of benefits associated with participation, or of a retaliatory response from senior members of a hierarchy in case of refusal to participate.
8. Has contraindications (known allergies, hypersensitivity, or intolerance) to the use of BNT314. A patient with a history of hypersensitivity to any component/excipients of BNT314 is also excluded.
9. Are pregnant or breastfeeding and cannot discontinue breastfeeding for the duration of the study and for 4 months after receiving the last dose of BNT314.
* Ongoing or active infection requiring treatment with anti-infective therapy administered less than 2 weeks prior to first dose.
* Symptomatic congestive heart failure (Grade III or IV as classified by the New York Heart Association), unstable angina pectoris, or symptomatic untreated cardiac arrhythmia. Treated and/or asymptomatic cardiac arrythmia/atrial fibrillation will be allowed.
* History of arterial thrombosis or pulmonary embolism within 6 months before the first dose of study treatment.
* History of myocardial infarction within 6 months before the first dose of study treatment.
* Uncontrolled hypertension defined as systolic blood pressure ≥160 mm Hg and/or diastolic blood pressure ≥100 mm Hg, despite optimal medical management.
* Prolonged QTc interval at baseline of ≥470 milliseconds using Fridericia's QT correction formula.
* Ongoing or recent (within one year of screening) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk for immune-related adverse events.
* History of:
* Grade 2 immune-mediated myocarditis/colitis/pneumonitis that led to checkpoint inhibitor (CPI) discontinuation. Patients experiencing other Grade 2 immune-mediated adverse events that led to CPI discontinuation, require discussion with the sponsor.
* Any Grade ≥3 immune-mediated adverse events that led to CPI discontinuation.
* Patients with Grade 3 adverse events that led to CPI discontinuation but resolved within 21 days without sequalae may also be considered for discussion with the sponsor.
* History of chronic liver disease (e.g., alcoholic hepatitis or nonalcoholic steatohepatitis, drug-related or autoimmune hepatitis) or evidence of hepatic cirrhosis.
* History of non-treated intracerebral arteriovenous malformation (shunts), non-treated cerebral aneurysm, spinal cord compression (from disease), carcinomatous meningitis, or stroke will be excluded.
* History of acute or chronic pancreatitis of any etiology within 6 weeks prior to the start of study treatment.
* Ongoing pneumonitis or history of noninfectious pneumonitis that has required steroids or evidence of interstitial lung disease.
* Transient ischemic attack less than one month prior to screening will be excluded.
* History of brain/central nervous system (CNS) metastases. Patients with newly identified or known unstable or symptomatic CNS metastases will be excluded. Patients with previously treated brain metastases are allowed provided lesions are radiologically stable (i.e., without evidence of progression) for at least 28 days by repeat imaging, latest imaging performed maximum 6 weeks prior to Cycle 1, Day 1.
* Serious, non-healing wound, skin ulcer (of any grade), or bone fracture will be excluded.
* Other concurrent severe and/or uncontrolled medical condition that would, in the investigator's judgment, contraindicate patient participation in this clinical study (e.g., acute or chronic pancreatitis, active hepatitis). Known primary immunodeficiencies, either cellular (e.g., DiGeorge syndrome, T-cell negative severe combined immunodeficiency \[SCID\] or combined T- and B-cell immunodeficiencies (e.g., T- and B-cell negative SCID, Wiskott Aldrich syndrome, ataxia telangiectasia, common variable immunodeficiency).
* Major surgery within 3 weeks before signature of the ICF unless fully recovered from the surgery in the opinion of the investigator.
* Any positive test for hepatitis B (defined as positive for hepatitis B surface antigen or hepatitis B virus DNA), indicating acute or chronic infection.
* Any positive test for hepatitis C (defined as positive for hepatitis C virus antibody or hepatitis C virus RNA), indicating acute or chronic infection.
2. Prior therapy:
* Radiotherapy within 14 days prior to first BNT314 administration. Palliative radiotherapy will be allowed, but not to target lesions.
* Any epithelial cell adhesion molecule- or 4-1BB-targeting treatment.
* Treatment with an anticancer agent within 4 weeks or for systemic therapies after at least five half-lives of the drug, whichever is shorter, prior to study treatment administration.
* Patient has received any investigational agent (including investigational vaccines) or used an invasive investigational medical device within 28 days before the planned first dose of BNT314 or is currently enrolled in an (another) interventional study. Patients who are in the follow-up phase of an interventional study may participate if they have not received an investigational agent within 28 days (or five half-lives, whichever is longer) of the first dose of BNT314.
* Patient has a condition requiring systemic treatment with either corticosteroids (\>10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days of the first dose of BNT314. Inhaled or topical steroids, and adrenal or pituitary replacement steroid \>10 mg daily prednisone or equivalent, are permitted in the absence of active autoimmune disease.
* Patient has received granulocyte or granulocyte/macrophage colony stimulating factor (G-CSF/GM-CSF) support within 4 weeks prior to first BNT314 administration or is chronically transfusion dependent; G-CSF and other hematopoietic factors may be used in the management of acute toxicity (such as febrile neutropenia) or prophylactically, when clinically indicated at the investigator's discretion.
* Received any live vaccine within 30 days prior to the start of study treatment.
3. Known alcohol dependency within 6 months enrollment in this study.
4. Planned enrollment in another study of an IMP, starting after Visit D1 and continuously until the last planned visit in this study.
5. Have a medical, psychological, or social condition which, in the opinion of the investigator, could compromise their wellbeing if they participate in the study, or that could prevent, limit, or confound the protocol specified assessments or procedures, or that could impact adherence to protocol-described requirements.
6. Are subject to exclusion periods from another investigational study.
7. Are vulnerable individuals as per International Council for Harmonisation E6 definition, i.e., are individuals whose willingness to participate in a clinical study may be unduly influenced by the expectation, whether justified or not, of benefits associated with participation, or of a retaliatory response from senior members of a hierarchy in case of refusal to participate.
8. Has contraindications (known allergies, hypersensitivity, or intolerance) to the use of BNT314. A patient with a history of hypersensitivity to any component/excipients of BNT314 is also excluded.
9. Are pregnant or breastfeeding and cannot discontinue breastfeeding for the duration of the study and for 4 months after receiving the last dose of BNT314.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Genmab
INDUSTRY
Sponsor Role
collaborator
BioNTech SE
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
BioNTech Responsible Person
Role: STUDY_DIRECTOR
BioNTech SE
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
START Midwest
Grand Rapids, Michigan, United States
Site Status
Carolina BioOncology Institute, LLC
Huntersville, North Carolina, United States
Site Status
Cleveland Clinic
Cleveland, Ohio, United States
Site Status
GZA Ziekenhuizen
Antwerp, , Belgium
Site Status
CHU de Liège
Liège, , Belgium
Site Status
Rigshospitalet
Copenhagen, , Denmark
Site Status
National Cancer Center Hospital East
Kashiwanoha, , Japan
Site Status
Hospital Quironsalud Barcelona (NEXT Barcelona)
Barcelona, , Spain
Site Status
Hospital Fund. Jiménez Dia
Madrid, , Spain
Site Status
Hospital HM Univ. Sanchinarro, Ensayos START
Madrid, , Spain
Site Status
Clinica Universidad de Navarra
Pamplona, , Spain
Site Status
Royal Marsden Hospital - London
London, , United Kingdom
Site Status
The Christie Hospital
Manchester, , United Kingdom
Site Status
Northern Centre for Cancer Care
Newcastle, , United Kingdom
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Belgium
Denmark
Japan
Spain
United Kingdom
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-506053-38-00
Identifier Type: CTIS
Identifier Source: secondary_id
1008686
Identifier Type: OTHER
Identifier Source: secondary_id
BNT314-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors
NCT06771921
TERMINATED
PHASE1/PHASE2
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
NCT06276491
RECRUITING
PHASE1
This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)
NCT03449381
COMPLETED
PHASE1
Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy
NCT06391775
TERMINATED
PHASE1/PHASE2
Dose Escalation Trial of BNT152+153 in Patients With Cancer
NCT04710043
COMPLETED
PHASE1
GEN1046 Safety Trial in Patients With Malignant Solid Tumors
NCT03917381
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
NCT07186842
RECRUITING
PHASE1/PHASE2
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
NCT04272034
TERMINATED
PHASE1
A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors
NCT02697591
COMPLETED
PHASE1/PHASE2
A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors
NCT03762447
COMPLETED
PHASE1
A First-in-human of Multiplle Doses of BB-1709 in Subjects With Locally Advanced/Metastatic Solid Tumors
NCT06241898
RECRUITING
PHASE1
A Dose-escalation Study in Subjects With Advanced Malignancies
NCT01195311
COMPLETED
PHASE1
To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06752681
RECRUITING
PHASE1
Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors
NCT06234397
RECRUITING
PHASE1
A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
NCT02013804
COMPLETED
PHASE1
Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors
NCT04780217
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
NCT00794781
COMPLETED
PHASE1
Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors
NCT06573294
RECRUITING
PHASE1
A Study of Dose Escalation of IBI321 in Patients With Advanced Solid Tumors
NCT04911894
COMPLETED
PHASE1
Weekly BI 836880 in Patients With Advanced Solid Tumors
NCT02689505
COMPLETED
PHASE1
A Study of JNJ-63898081 in Participants With Advanced Stage Solid Tumors
NCT03926013
COMPLETED
PHASE1
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411
NCT04101357
TERMINATED
PHASE1/PHASE2
A Trial to Find the Safe Dose for BI 905681 in Patients With Incurable Tumours or Tumours That Have Spread
NCT04147247
COMPLETED
PHASE1
Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors
NCT00820560
COMPLETED
PHASE1
First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
NCT05438329
RECRUITING
PHASE1/PHASE2